Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265096 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis
A Phase 3 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 3
- Development phase
- 407
- Enrollment target
NCT00265096 is a Phase 3 study that has completed, run by Centocor. The registered enrollment target is 407 participants.
The verdict
NCT00265096, a Phase 3 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 407 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy (improvement of signs and symptoms) of subcutaneous (under the skin) injections of golimumab for the treatment of active psoriatic arthritis (PsA). Efficacy will be measured by reduction in the signs and symptoms of active PsA, including effects on joint pain and swelling, changes on x-ray related to joint damage, psoriasis skin lesions, physical function, and quality of life.
Interventions
- BIOLOGICAL golimumab
- BIOLOGICAL Placebo; golimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2005-12 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265096
The ClinicalTrials.gov registry entry for NCT00265096 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which golimumab is the first listed.
NCT00265096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265096 about?
NCT00265096 is a clinical study titled "A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis". The purpose of this study is to evaluate the safety and efficacy (improvement of signs and symptoms) of subcutaneous (under the skin) injections of golimumab for the treatment of active psoriatic arthritis (PsA). Efficacy will be measured by reduction in the signs and symptoms of active PsA, includi...
What is the current status of trial NCT00265096?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 407 participants. The study started on 2005-12. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00265096?
The interventions under investigation include: golimumab (BIOLOGICAL), Placebo; golimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00265096?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.